All In Biotech

Drug Trial Radar · NCT01763866

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,067 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,067

Actual

Start

Jan 15, 2013

Primary completion

Nov 12, 2013

Study completion Dec 4, 2013

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jan 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.

Conditions

  • Hyperlipidemia

Interventions

  • EvolocumabBiological

    Administered by subcutaneous injection

  • EzetimibeDrug

    Administered orally once a day

  • Placebo to EvolocumabDrug

    Administered by subcutaneous injection

  • Placebo to EzetimibeDrug

    Administered orally once a day

  • AtorvastatinDrug

    Administered orally once a day

  • RosuvastatinDrug

    Administered orally once a day

  • SimvastatinDrug

    Administered orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12Time frame: Baseline and Week 12
  2. Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12Time frame: Baseline and Weeks 10 and 12

Locations

244 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Carmichael, California

  • Research Site

    Encino, California

  • Research Site

    Long Beach, California

  • Research Site

    Newport Beach, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Ana, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Torrance, California

  • Research Site

    Tustin, California

  • Research Site

    Westlake Village, California

  • Research Site

    Littleton, Colorado

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Hammond, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Valparaiso, Indiana

  • Research Site

    Iowa City, Iowa

  • Research Site

    Crestview Hills, Kentucky

  • Research Site

    Monroe, Louisiana

  • Research Site

    Auburn, Maine

  • Research Site

    Bangor, Maine

  • Research Site

    Portland, Maine

  • Research Site

    Baltimore, Maryland

  • Research Site

    Ypsilanti, Michigan

  • Research Site

    Tupelo, Mississippi

  • Research Site

    Billings, Montana

  • Research Site

    Voorhees Township, New Jersey

  • Research Site

    Manlius, New York

  • Research Site

    Rochester, New York

Showing 40 of 244 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.